Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
Want to see HK:2252 full AI Analyst Report?
Top Page
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
(2252)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$25.00
▼(-26.77% Downside)
Action:Reiterated
Date:05/02/26
The score is held back primarily by weak financial quality—continued net losses, deeply negative ROE, and ongoing cash burn—despite strong 2025 revenue acceleration and improved leverage. Technicals are supportive with an upward trend and positive MACD, but valuation remains difficult to justify on earnings due to negative P/E.
Positive Factors
Revenue Acceleration
A sustained revenue acceleration (+~61% in 2025) signals improving commercial traction for surgical robotic platforms. If durable, this growth supports scale advantages, strengthens hospital adoption, and underpins future margin expansion and recurring instrument/service revenue over the medium term.
Negative Factors
Sustained Net Losses
A ~-45% net margin in 2025 shows the business remains loss-making at scale, eroding retained capital and requiring external funding. Persistent operating losses constrain reinvestment, limit free-cash generation, and delay durable path to self-funded growth until operating margins materially improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Acceleration
A sustained revenue acceleration (+~61% in 2025) signals improving commercial traction for surgical robotic platforms. If durable, this growth supports scale advantages, strengthens hospital adoption, and underpins future margin expansion and recurring instrument/service revenue over the medium term.
Read all positive factors
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$26.29B
Dividend YieldN/A
Average Volume (3M)5.91M
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue Growth114.97%
EPS Growth63.21%
CountryHK
Employees450
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.27Price Target Upside15.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$1.13B
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic...
How the Company Makes Money
null...
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
45
Neutral
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 551.07M | 257.25M | 104.59M | 21.60M | 2.15M |
| Gross Profit | 266.62M | 86.22M | 14.69M | 6.56M | 919.00K |
| EBITDA | -96.84M | -413.34M | -893.36M | -1.05B | -543.84M |
| Net Income | -249.66M | -642.41M | -1.01B | -1.14B | -582.92M |
Balance Sheet | |||||
| Total Assets | 1.34B | 1.28B | 1.43B | 1.93B | 2.79B |
| Cash, Cash Equivalents and Short-Term Investments | 640.42M | 612.23M | 507.71M | 747.96M | 1.94B |
| Total Debt | 426.37M | 691.33M | 560.42M | 219.95M | 204.68M |
| Total Liabilities | 935.07M | 1.02B | 926.15M | 522.25M | 401.73M |
| Stockholders Equity | 410.85M | 278.20M | 519.48M | 1.42B | 2.39B |
Cash Flow | |||||
| Free Cash Flow | -38.83M | -340.21M | -634.30M | -1.09B | -674.47M |
| Operating Cash Flow | -36.30M | -298.12M | -567.84M | -898.48M | -540.49M |
| Investing Cash Flow | 2.55M | -47.60M | -58.38M | -267.82M | -396.57M |
| Financing Cash Flow | 66.32M | 449.96M | 385.68M | -27.95M | 1.39B |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis
Negative
34.14
Price Trends
28.09
Negative
27.43
Negative
26.09
Negative
Market Momentum
-0.97
Positive
38.67
Neutral
34.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2252, the sentiment is Negative. The current price of 34.14 is above the 20-day moving average (MA) of 27.62, above the 50-day MA of 28.09, and above the 200-day MA of 26.09, indicating a bearish trend. The MACD of -0.97 indicates Positive momentum. The RSI at 38.67 is Neutral, neither overbought nor oversold. The STOCH value of 34.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2252.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$6.56B | 16.66 | 11.91% | 1.26% | 10.19% | 23.70% | |
65 Neutral | HK$5.38B | 24.85 | 10.38% | 1.50% | 3.83% | -27.04% | |
59 Neutral | HK$3.09B | 58.63 | 2.04% | ― | 91.69% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$26.29B | -90.43 | -52.78% | ― | 114.97% | 63.21% | |
48 Neutral | HK$14.42B | 32.50 | 6.07% | ― | -3.62% | ― | |
41 Neutral | HK$2.11B | -1.07 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
25.34
10.26
68.04%
HK:0853
MicroPort Scientific
7.52
0.24
3.30%
HK:1789
AK Medical Holdings Ltd.
5.85
0.24
4.28%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.66
-2.54
-60.48%
HK:2172
MicroPort NeuroTech Limited
9.20
-0.90
-8.91%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.34
1.70
30.14%
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events
MicroPort MedBot Proposes New Share Scheme to Replace Existing Incentive Plans
May 14, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. plans to adopt a new share scheme that will allow the company to grant new and existing shares, as well as options over new shares, to eligible participants as incentives for their contributions or poten...
MicroPort MedBot Sets 2026 AGM With New Capital Mandates on the Table
May 14, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. has called its annual general meeting for 5 June 2026 in Shanghai, where shareholders will review the 2025 annual report, supervisory committee report and proposed profit distribution plan, as well as vo...
MicroPort MedBot Completes Near-Full H Share Circulation to Boost Liquidity
Apr 23, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd., a Hong Kong-listed Chinese medical technology company specializing in robotic-assisted surgical systems, continues to refine its capital structure to support its growth in domestic and global healthcare...
MicroPort MedBot Doubles Revenue as Toumai Surgical Robot Drives Overseas Surge
Mar 26, 2026
Shanghai MicroPort MedBot reported a sharp ramp-up in commercial performance for 2025, with revenue surging 114.2% year-on-year to RMB551.1 million, driven primarily by breakthrough progress in the rollout of its Toumai laparoscopic surgical robot...
Shanghai MicroPort MedBot Sets March 2026 Board Meeting to Approve 2025 Results
Mar 16, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. has scheduled a board meeting for 26 March 2026 to review and approve the audited financial results for the year ended 31 December 2025 and to authorize their release. The board will also consider whethe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.